Faculty

Faculty

Lauren Cobb

MD

The University of Texas MD Anderson Cancer Center, Houston, Texas

Associate Professor, Department of Gynecologic Oncology and Reproductive Medicine

Faculty

Rachel N Grisham

MD

Memorial Sloan Kettering Cancer Center, New York, New York

Attending Physician, Section Head, Ovarian Cancer, Director, Gynecologic Medical Oncology, MSKCC Westchester

Faculty

Elizabeth H Stover

MD, PhD

Harvard Medical School, Boston, Massachusetts

Assistant Professor, Medicine

Dana-Farber Cancer Institute, Boston, Massachusetts

Oncologist, Medical Oncology

TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of ovarian cancer.

LEARNING OBJECTIVES

• Assess available efficacy and safety findings with a RAF/MEK clamp in combination with a FAK inhibitor for patients with recurrent low-grade serous ovarian cancer in order to optimally incorporate available agents into current management algorithms.
• Recognize the spectrum, frequency and severity of adverse events associated with a RAF/MEK clamp with a FAK inhibitor, and implement supportive care strategies to minimize and manage toxicities.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 0.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
To receive credit for this activity, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Grisham — Advisory Committees and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, GSK, ImmunoGen Inc, Incyclix Bio, Incyte Corporation, Lilly, Merck, Verastem Inc.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, and Verastem Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

This activity is supported by an educational grant from Verastem Inc.

Release date: September 2026
Expiration date: September 2027

Banerjee S et al. Defactinib with avutometinib in patients with solid tumors: The phase 1 FRAME trial. Nat Med 2025;31(9):3074-80. Abstract

Banerjee SN et al. Efficacy and safety of avutometinib ± defactinib in recurrent low-grade serous ovarian cancer: Primary analysis of ENGOT-OV60/GOG-3052/RAMP 201. J Clin Oncol 2025;43(25):2782-92. Abstract

Cheng Y et al. Exposure-response analysis for avutometinib in combination with defactinib in low-grade serous ovarian cancer. SGO 2026;Abstract 1112.

Demirkiran C et al. Preclinical efficacy of the estrogen receptor degrader fulvestrant in combination with RAF/MEK clamp avutometinib and FAK inhibitor in low-grade serous ovarian cancer with acquired resistance to chemotherapy and aromatase inhibitor. SGO 2025;Abstract 2193.

Fader A et al. Results of a randomized phase III trial of letrozole alone versus paclitaxel and carboplatin followed by letrozole as initial treatment for patients with stage II-IV ovarian, fallopian tube, or primary peritoneal low-grade serous carcinoma (NRG-GY019, NCT04095364). SGO 2026;Abstract LBA02.

Grisham R et al. Long-term efficacy and safety of avutometinib + defactinib in patients with recurrent low-grade serous ovarian cancer: Results from ENGOT-OV60/GOG-3052/RAMP 201. SGO 2026;Abstract LBA01.

Grisham R et al. OG-3097/ENGOT-ov81/GTG-UK/RAMP 301: A phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancer. Int J Gynecol Cancer 2025;35(11):101832. Abstract

Hollis RL et al. Molecular profiling and tumor biomarker analysis of GOG281/LOGS: A positive late-phase trial of trametinib for recurrent/persistent low-grade serous ovarian carcinoma. Clin Cancer Res 2026;32(4):724-34. Abstract

Manning-Geist B et al. Combination targeted and Hormonal treAtMEnt of Low-gradE serous Ovarian cancer in the upfroNt setting (CHAMELEON). SGO 2026;Abstract 272.

Faculty

Faculty

Rachel N Grisham

MD

Memorial Sloan Kettering Cancer Center, New York, New York

Attending Physician, Section Head, Ovarian Cancer, Director, Gynecologic Medical Oncology, MSKCC Westchester

TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of ovarian cancer.

LEARNING OBJECTIVES

• Understand the incidence, clinical characteristics and prognosis of low-grade serous ovarian cancer (LGSOC) and appreciate how these factors differentiate it from high-grade serous ovarian cancer.
• Assess available clinical evidence documenting the efficacy and safety of various local and systemic management approaches for LGSOC, and determine the current indications for these strategies.
• Comprehend the scientific rationale for combined targeting of the mitogen-activated protein kinase signaling pathway for LGSOC with RAF/MEK clamp and FAK inhibition.
• Assess available efficacy and safety findings with RAF/MEK clamp and FAK inhibitors for patients with recurrent LGSOC in order to optimally incorporate available agents into current management algorithms.
• Recognize the spectrum, frequency and severity of adverse events associated with RAF/MEK clamp and FAK inhibitors, and implement supportive care strategies to minimize and manage resultant toxicities.
• Recall the designs of ongoing clinical trials evaluating novel agents and strategies for LGSOC, and counsel appropriate patients about availability and participation.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 0.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

AMERICAN BOARD OF SURGERY (ABS) — CONTINUOUS CERTIFICATION (CC) 
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
To receive credit for this activity, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Grisham — Advisory Committees and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, GSK, ImmunoGen Inc, Incyclix Bio, Incyte Corporation, Lilly, Merck, Verastem Inc.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, and Verastem Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

This activity is supported by an educational grant from Verastem Inc.

Release date: September 2026
Expiration date: September 2027

Banerjee S et al. Defactinib with avutometinib in patients with solid tumors: The phase 1 FRAME trial. Nat Med 2025;31(9):3074-80. Abstract

Banerjee SN et al. Efficacy and safety of avutometinib ± defactinib in recurrent low-grade serous ovarian cancer: Primary analysis of ENGOT-OV60/GOG-3052/RAMP 201. J Clin Oncol 2025;43(25):2782-92. Abstract

Cheng Y et al. Exposure-response analysis for avutometinib in combination with defactinib in low-grade serous ovarian cancer. SGO 2026;Abstract 1112.

Demirkiran C et al. Preclinical efficacy of the estrogen receptor degrader fulvestrant in combination with RAF/MEK clamp avutometinib and FAK inhibitor in low-grade serous ovarian cancer with acquired resistance to chemotherapy and aromatase inhibitor. SGO 2025;Abstract 2193.

Fader A et al. Results of a randomized phase III trial of letrozole alone versus paclitaxel and carboplatin followed by letrozole as initial treatment for patients with stage II-IV ovarian, fallopian tube, or primary peritoneal low-grade serous carcinoma (NRG-GY019, NCT04095364). SGO 2026;Abstract LBA02.

Grisham R et al. Long-term efficacy and safety of avutometinib + defactinib in patients with recurrent low-grade serous ovarian cancer: Results from ENGOT-OV60/GOG-3052/RAMP 201. SGO 2026;Abstract LBA01.

Grisham R et al. OG-3097/ENGOT-ov81/GTG-UK/RAMP 301: A phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancer. Int J Gynecol Cancer 2025;35(11):101832. Abstract

Hollis RL et al. Molecular profiling and tumor biomarker analysis of GOG281/LOGS: A positive late-phase trial of trametinib for recurrent/persistent low-grade serous ovarian carcinoma. Clin Cancer Res 2026;32(4):724-34. Abstract

Manning-Geist B et al. Combination targeted and Hormonal treAtMEnt of Low-gradE serous Ovarian cancer in the upfroNt setting (CHAMELEON). SGO 2026;Abstract 272.

Faculty

Faculty

Floor J Backes

MD

The Ohio State University College of Medicine, The James Cancer Hospital and Solove Research Institute, Columbus, Ohio

Professor, Larry J Copeland Professorship in Gynecologic Oncology, Director of Clinical Research, Associate Fellowship Director, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology

Faculty

Matthew A Powell

MD

Washington University School of Medicine, St Louis, Missouri

Ira C and Judith Gall Professor, Division of Gynecologic Oncology, Chair, Uterine Corpus Committee, National Cancer Institute-Sponsored NRG Oncology

Moderator

Ritu Salani

MD, MBA

David Geffen School of Medicine at UCLA, Los Angeles, California

Director, Division of Gynecologic Oncology, Professor, Department of Obstetrics and Gynecology

TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of endometrial cancer.

LEARNING OBJECTIVES

• Assess the clinical and biological characteristics of the various histologic subtypes and molecular subgroups of endometrial cancer (EC), and consider the implications for prognosis and therapeutic decision-making.
• Understand the biological rationale for and available data with the combination of PARP inhibitors with immune checkpoint inhibitor therapy for patients with advanced or metastatic EC.
• Recognize available data with anti-PD-1/PD-L1 antibodies in combination with agents targeting the VEGF pathway, and select patients with metastatic EC for treatment with this novel approach.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 0.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for this activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

AMERICAN BOARD OF SURGERY (ABS) — CONTINUOUS CERTIFICATION (CC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
To receive credit for this activity, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Backes — Advisory Committees and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Eisai Inc, Genmab US Inc, GSK, ImmunoGen Inc, Merck, Tubulis; Contracted Research: ImmunoGen Inc, Merck, Natera Inc; Data and Safety Monitoring Boards/Committees: MacroGenics Inc. Dr Powell — Consulting Agreements: Eisai Inc, GSK, Merck; Contracted Research: GSK. 

CONSULTING CLINICAL INVESTIGATORS

Prof Ledermann — Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Flindr, GSK, ImmunoGen Inc, MSD, Novocure Inc; Consulting Agreements: AbbVie Inc, GSK; Data and Safety Monitoring Boards/Committees: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Sutro Biopharma, Zentalis Pharmaceuticals; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, GSK, Medison Pharmaceuticals, MSD. Ursula Matulonis, MD — Advisory Committees: AbbVie Inc, Ascendis Pharma, Corcept Therapeutics Inc, Day One Biopharmaceuticals, GSK, Kaida BioPharma, Merck, NextCure, Whitehawk Therapeutics; Data and Safety Monitoring Boards/Committees: AstraZeneca Pharmaceuticals LP, MacroGenics Inc, Mural Oncology Inc, Symphogen A/S. Angeles Alvarez Secord, MD, MHSc — Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Foundation Medicine, Genmab US Inc, Gilead Sciences Inc, GSK, HistoSonics, Medtronic Inc, Merck; Clinical Trial Steering Committees: Genmab US Inc, OncoQuest Inc; Consulting Agreements: GSK, Merck; Contracted Research: AbbVie Inc, Aravive Inc, AstraZeneca Pharmaceuticals LP, Canaria Bio Inc, Daiichi Sankyo Inc, Ellipses Pharma, Genentech, a member of the Roche Group, Genmab US Inc, GSK, ImmunoGen Inc, Karyopharm Therapeutics, Merck, Mersana Therapeutics Inc, Myriad Genetic Laboratories Inc, OncoQuest Inc, TORL BioTherapeutics, Zentalis Pharmaceuticals; Stock Options/Stock — Public Companies: Stock in Amgen Inc and Johnson & Johnson, divested in June 2024.

MODERATOR

Dr Salani — Advisory Committees: AbbVie Inc, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Eisai Inc, Genmab US Inc, GSK, Merck, Pfizer Inc, Whitehawk Therapeutics; Nonrelevant Financial Relationships: UpToDate. 

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, and Verastem Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

This activity is supported by an educational grant from GSK.

Release date: September 2026
Expiration date: September 2027

Dr Backes

Erickson BK et al. Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study. Gynecol Oncol 2020;159(1):17-22. Abstract

Erickson BK et al. Targeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies. Curr Opin Obstet Gynecol 2020;32(1):57-64. Abstract

Eskander RN et al. Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: Overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial. Nat Med 2025;31(5):1539-46. Abstract

Halaska MJ et al. Pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer: Exploratory analysis of disease-specific survival from the phase 3 ENGOT-En11/GOG-3053/KEYNOTE-B21 study. ESGO 2025;Abstract.

Howitt BE et al. Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol 2015;1(9):1319-23. Abstract

Levine DA, on behalf of The Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497(7447):67-73. Abstract

Mirza MR et al. Dostarlimab+chemotherapy for the treatment of primary advanced or recurrent (A/R) endometrial cancer (EC): A placebo (PBO)-controlled randomised phase III trial (ENGOT-EN6-NSGO/GOG-3031/RUBY). ESMO 2023;Abstract VP2-2023.

Pignata S et al. MITO END-3: Efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy. Ann Oncol 2024;35(7):667-76. Abstract

Van Gorp T et al. ENGOT-en11/GOG-3053/KEYNOTE-B21: A randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer. Ann Oncol 2024;35(11):968-80. Abstract

Westin SN et al. Biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer: Exploratory analyses of the DUO-E/GOG-3041/ENGOT-EN10 trial. Gynecol Oncol 2026;206:54-64. Abstract

Westin SN et al. Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for endometrial cancer: Longitudinal changes in circulating tumor DNA. ASCO 2025;Abstract 5512.

Yen T-T et al. Molecular classification and emerging targeted therapy in endometrial cancer. Int J Gynecol Pathol 2020;39(1):26-35. Abstract

Dr Powell

Eskander RN et al. Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: Overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial. Nat Med 2025;31(5):1539-46. Abstract

Eskander RN et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer. N Engl J Med 2023;388(23):2159-70. Abstract

Miller DS et al. Carboplatin and paclitaxel for advanced endometrial cancer: Final overall survival and adverse event analysis of a phase III trial (NRG Oncology/GOG0209). J Clin Oncol 2020;38(33):3841-50. Abstract

Mirza M et al. Dostarlimab in combination with chemotherapy for the treatment of primary advanced or recurrent endometrial cancer: A placebo-controlled randomized phase 3 trial (ENGOT-EN6-NSGO/GOG-3031/RUBY). SGO 2023;Abstract LBA 11.

Moore K et al. Durvalumab plus carboplatin/paclitaxel followed by durvalumab with/without olaparib in endometrial cancer: Biomarkers, histological heterogeneity, baseline circulating tumor DNA and efficacy in the DUO-E mismatch repair proficient subpopulation. SGO 2025;Abstract.

Powell M et al. Overall survival among patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial. SGO 2024;Abstract.

Van Gorp T et al. ENGOT-en11/GOG-3053/KEYNOTE-B21: A randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer. ESMO 2024;Abstract LBA28.

Westin SN et al. Durvalumab plus carboplatin/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: The phase III DUO-E trial. J Clin Oncol 2024;42(3):283-99. Abstract

Westin SN et al. Durvalumab (durva) plus carboplatin/paclitaxel (CP) followed by maintenance (mtx) durva ± olaparib (ola) as a first-line (1L) treatment for newly diagnosed advanced or recurrent endometrial cancer (EC): Results from the phase III DUO-E/GOG-3041/ENGOT-EN10 trial. ESMO 2023;Abstract LBA41.

Dr Salani

Baurain J-F et al. Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as a firstline treatment for endometrial cancer: Overall survival and additional secondary efficacy endpoints by mismatch repair status in the DUO-E/GOG-3041/ENGOT-EN10 trial. SGO 2024;Abstract.

Konstantinopoulos PA et al. Evaluation of treatment with talazoparib and avelumab in patients with recurrent mismatch repair proficient endometrial cancer. JAMA Oncol 2022;8(9):1317-22. Abstract

Leslie KK et al. Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. Gynecol Oncol 2021;161(1):113-21. Abstract

Makker V et al. Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: Updated efficacy and safety from the randomized phase III study 309/KEYNOTE-775. J Clin Oncol 2023;41(16):2904-10. Abstract

Mirza MR et al. Dostarlimab for primary advanced or recurrent endometrial cancer. N Engl J Med 2023;388(23):2145-58. Abstract

Post CCB et al. Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial). Gynecol Oncol 2022;165(2):223-9. Abstract

Powell M et al. Chemotherapy with or without pembrolizumab followed by maintenance with olaparib or placebo for first-line treatment of advanced BRCA nonmutated epithelial ovarian cancer: Results from the randomized phase III ENGOT-OV43/GOG-3036/KEYLYNK-001 study. SGO 2025;Abstract.

Thiel KW et al. TP53 sequencing and p53 immunohistochemistry predict outcomes when bevacizumab is added to frontline chemotherapy in endometrial cancer: An NRG oncology/gynecologic oncology group study. J Clin Oncol 2022;40(28):3289-300. Abstract

Faculty

Faculty

Professor Andreas Hochhaus

Jena University Hospital, Comprehensive Cancer Center Central Germany, Campus Jena, Jena, Germany

Hematology/Oncology

TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of chronic myeloid leukemia.

LEARNING OBJECTIVES

• Evaluate factors, including patient age, comorbidities and personal preferences and drug side-effect profiles, that contribute to the selection and sequencing of therapies for newly diagnosed chronic-phase chronic myeloid leukemia (CML).
• Review the mechanism of action of and published efficacy and safety data with STAMP (specifically targeting the ABL myristoyl pocket) inhibitors for patients with newly diagnosed and relapsed/refractory (R/R) CML.
• Identify patients with newly diagnosed chronic-phase CML for whom initial treatment with a STAMP inhibitor would be appropriate.
• Establish an evidence-based approach to the selection and sequencing of available therapeutic options for patients with R/R CML.
• Implement a plan of care to recognize and manage class-effect and agent-specific toxicities associated with therapies commonly employed in the care of patients with CML.
• Counsel appropriately selected patients regarding available research with and ongoing trials evaluating novel agents and strategies under investigation for CML to facilitate participation in active research protocols.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Interview: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Lecture: Research To Practice designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the participant to earn up to 1.25 (interview) or 0.75 (lecture) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
To receive credit for each activity, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation (interview, lecture). 

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Prof Hochhaus has no relevant financial relationships to disclose.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, and Verastem Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor. 

These activities are supported by an educational grant from Novartis.

Release date: September 2026
Expiration date: September 2027

Apperley JF et al. 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Leukemia 2025;39(8):1797-813. Abstract

Branford S et al. Somatic mutations at diagnosis in patients with chronic phase CML receiving frontline imatinib are associated with a higher rate of treatment failure: First analysis from the International CML Foundation (iCMLf) genomics alliance on the HARMONY platform. ASH 2025;Abstract 75.

Ernst T et al. Improved long-term tolerability and efficacy of asciminib-based combination therapies in newly diagnosed CML patients — The FASCINATION trial. ASH 2025;Abstract 903.

Ernst P et al. Treatment expectations and goals among patients with chronic myeloid leukemia in Germany: A patient-centered perspective. Leukemia 2026;40(1):29-36. Abstract

Hehlmann R et al. High-risk additional chromosomal abnormalities at low blast counts herald death by CML. Leukemia 2020;34(8):2074-86. Abstract

Hochhaus A et al. Asciminib (ASC) shows superior tolerability vs nilotinib (NIL) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Primary endpoint results of the phase (ph) 3b ASC4START trial. EHA 2025;Abstract S166.

Hochhaus A et al. Nilotinib vs nilotinib + peg-interferon αlpha induction and nilotinib or peg-interferon αlpha maintenance therapy for newly diagnosed chronic myeloid leukemia patients. The TIGER trial. EHA 2023;Abstract S157.

Hughes T et al. ASC4FIRST wk 144 analysis: Continued superior efficacy and favorable safety of asciminib vs investigator-selected tyrosine kinase inhibitors in newly diagnosed chronic phase chronic myeloid leukemia. EHA 2026;Abstract S160.

Hughes T et al. Improved long-term tolerability with asciminib (ASC) vs investigator-selected (IS) tyrosine kinase inhibitors (TKIs) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Week 96 exploratory analysis of the phase 3 ASC4FIRST trial. ASH 2025;Abstract 5549.

Hughes TP et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med 2019;381(24):2315-26. Abstract

Jabbour E et al. CARDINAL: A phase 1 study of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor for patients with previously treated CML. ASH 2025;Abstract 901.

Kantarjian HM et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia 2021;35(2):440-53. Abstract

La Rosée P et al. Improved tolerability with dasatinib 5 days compared to 7 days per week in patients with chronic myeloid leukemia in chronic phase. Final results of the DasaHiT trial. EHA 2024;Abstract S172.

Lang F et al. Improving chronic myeloid leukemia management and quality of life: Patient and physician survey on unmet needs from the CML SUN survey. Haematologica 2026;111(2):597-608. Abstract

Passweg JR et al. The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T’s come into focus. Bone Marrow Transplant 2020;55(8):1604-13. Abstract

Qiang W et al. Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib. Leukemia 2017;31(12):2844-7. Abstract

Réa D, Hughes TP. Development of asciminib, a novel allosteric inhibitor of BCR-ABL1. Crit Rev Oncol Hematol 2022:171:103580. Abstract

Sembill S et al. Catch-up growth after switch to asciminib in a twin with chronic myeloid leukaemia. Lancet 2025;406(10519):2533-5. Abstract

Tiribelli M et al. The role of allogeneic transplantation in chronic myeloid leukemia in 2023: A case-based concise review. Hemato 2023;4(3):250-8. Abstract

Faculty

Faculty

Professor Andreas Hochhaus

Jena University Hospital, Comprehensive Cancer Center Central Germany, Campus Jena, Jena, Germany

Hematology/Oncology

TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of chronic myeloid leukemia.

LEARNING OBJECTIVES

• Evaluate factors, including patient age, comorbidities and personal preferences and drug side-effect profiles, that contribute to the selection and sequencing of therapies for newly diagnosed chronic-phase chronic myeloid leukemia (CML).
• Review the mechanism of action of and published efficacy and safety data with STAMP (specifically targeting the ABL myristoyl pocket) inhibitors for patients with newly diagnosed and relapsed/refractory (R/R) CML.
• Identify patients with newly diagnosed chronic-phase CML for whom initial treatment with a STAMP inhibitor would be appropriate.
• Establish an evidence-based approach to the selection and sequencing of available therapeutic options for patients with R/R CML.
• Implement a plan of care to recognize and manage class-effect and agent-specific toxicities associated with therapies commonly employed in the care of patients with CML.
• Counsel appropriately selected patients regarding available research with and ongoing trials evaluating novel agents and strategies under investigation for CML to facilitate participation in active research protocols.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Interview: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Lecture: Research To Practice designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the participant to earn up to 1.25 (interview) or 0.75 (lecture) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
To receive credit for each activity, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation (interview, lecture). 

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Prof Hochhaus has no relevant financial relationships to disclose.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, and Verastem Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor. 

These activities are supported by an educational grant from Novartis.

Release date: September 2026
Expiration date: September 2027

Apperley JF et al. 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Leukemia 2025;39(8):1797-813. Abstract

Branford S et al. Somatic mutations at diagnosis in patients with chronic phase CML receiving frontline imatinib are associated with a higher rate of treatment failure: First analysis from the International CML Foundation (iCMLf) genomics alliance on the HARMONY platform. ASH 2025;Abstract 75.

Ernst T et al. Improved long-term tolerability and efficacy of asciminib-based combination therapies in newly diagnosed CML patients — The FASCINATION trial. ASH 2025;Abstract 903.

Ernst P et al. Treatment expectations and goals among patients with chronic myeloid leukemia in Germany: A patient-centered perspective. Leukemia 2026;40(1):29-36. Abstract

Hehlmann R et al. High-risk additional chromosomal abnormalities at low blast counts herald death by CML. Leukemia 2020;34(8):2074-86. Abstract

Hochhaus A et al. Asciminib (ASC) shows superior tolerability vs nilotinib (NIL) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Primary endpoint results of the phase (ph) 3b ASC4START trial. EHA 2025;Abstract S166.

Hochhaus A et al. Nilotinib vs nilotinib + peg-interferon αlpha induction and nilotinib or peg-interferon αlpha maintenance therapy for newly diagnosed chronic myeloid leukemia patients. The TIGER trial. EHA 2023;Abstract S157.

Hughes T et al. ASC4FIRST wk 144 analysis: Continued superior efficacy and favorable safety of asciminib vs investigator-selected tyrosine kinase inhibitors in newly diagnosed chronic phase chronic myeloid leukemia. EHA 2026;Abstract S160.

Hughes T et al. Improved long-term tolerability with asciminib (ASC) vs investigator-selected (IS) tyrosine kinase inhibitors (TKIs) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Week 96 exploratory analysis of the phase 3 ASC4FIRST trial. ASH 2025;Abstract 5549.

Hughes TP et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med 2019;381(24):2315-26. Abstract

Jabbour E et al. CARDINAL: A phase 1 study of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor for patients with previously treated CML. ASH 2025;Abstract 901.

Kantarjian HM et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia 2021;35(2):440-53. Abstract

La Rosée P et al. Improved tolerability with dasatinib 5 days compared to 7 days per week in patients with chronic myeloid leukemia in chronic phase. Final results of the DasaHiT trial. EHA 2024;Abstract S172.

Lang F et al. Improving chronic myeloid leukemia management and quality of life: Patient and physician survey on unmet needs from the CML SUN survey. Haematologica 2026;111(2):597-608. Abstract

Passweg JR et al. The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T’s come into focus. Bone Marrow Transplant 2020;55(8):1604-13. Abstract

Qiang W et al. Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib. Leukemia 2017;31(12):2844-7. Abstract

Réa D, Hughes TP. Development of asciminib, a novel allosteric inhibitor of BCR-ABL1. Crit Rev Oncol Hematol 2022:171:103580. Abstract

Sembill S et al. Catch-up growth after switch to asciminib in a twin with chronic myeloid leukaemia. Lancet 2025;406(10519):2533-5. Abstract

Tiribelli M et al. The role of allogeneic transplantation in chronic myeloid leukemia in 2023: A case-based concise review. Hemato 2023;4(3):250-8. Abstract

Faculty

Faculty

Professor Solange Peters

MD, PhD

Lausanne University Hospital, Lausanne, Switzerland

Medical Oncology Chair, Oncology Department Director

Faculty

Joshua K Sabari

MD

Perlmutter Cancer Center, New York, New York

Medical Director, Thoracic Medical Oncology

NYU Grossman School of Medicine, New York, New York

Assistant Professor, Department of Medicine

TARGET AUDIENCE
This activity is intended for medical oncologists, hematologists, hematology-oncology fellows, radiation oncologists, surgeons and other allied healthcare professionals involved in the treatment of lung cancer.

LEARNING OBJECTIVES

• Recognize the molecular heterogeneity of non-small cell lung cancer (NSCLC), and appreciate the biological rationale for efforts to exploit documented abnormalities in the KRAS pathway.
• Assess published clinical trial data informing the use of FDA-approved KRAS G12C inhibitors for patients with previously treated metastatic NSCLC harboring a KRAS G12C mutation, and optimally incorporate these agents into current management algorithms.
• Develop an understanding of the rationale for, unique characteristics of and available and emerging data with novel small-molecule inhibitors of KRAS G12C in order to determine the potential applicability of these agents.
• Appreciate the side effects and toxicities associated with approved and investigational KRAS G12C inhibitors, and enact support measures to maintain quality of life and continuation of treatment.
• Recollect the designs of ongoing clinical trials attempting to further define the optimal use of KRAS G12C inhibitors for lung cancer in order to counsel patients regarding study participation.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 1.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

AMERICAN BOARD OF SURGERY (ABS) — CONTINUOUS CERTIFICATION (CC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
To receive credit for this activity, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Prof Peters — Advisory Committees and Consulting Agreements (All Fees to Institution): AbbVie Inc, Amgen Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeOne, BerGenBio ASA, Bicycle Therapeutics, Biocartis, BioInvent, BioNTech SE, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Daiichi Sankyo Inc, Debiopharm, F-star Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, GSK, HUTCHMED, Illumina, Incyte Corporation, Ipsen Biopharmaceuticals Inc, iTeos Therapeutics, Janssen Biotech Inc, Lilly, Merck Serono, MSD, Novartis, Novocure Inc, Nuvalent, Nuvation Bio Inc, Nykode Therapeutics, Pfizer Inc, PharmaMar, Promontory Therapeutics Inc, Qlucore AB, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc, Transgene, Zymeworks Inc; Speakers Bureaus (All Fees to Institution): AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Foundation Medicine, Genentech, a member of the Roche Group, GSK, Illumina, Ipsen Biopharmaceuticals Inc, Lilly, MSD, Novartis, Pfizer Inc, Sanofi, Takeda Pharmaceuticals USA Inc.

Dr Sabari — Advisory Committees and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, EMD Serono Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Mirati Therapeutics Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Contracted Research: Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Janssen Biotech Inc, Johnson & Johnson, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Mirati Therapeutics Inc, Regeneron Pharmaceuticals Inc.

MODERATOR — Dr Love  is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, and Verastem Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

This activity is supported by an educational grant from Lilly.

Release date: September 2026
Expiration date: September 2027

Burns TF et al. Efficacy and safety of olomorasib in combination with pembrolizumab in treatment of patients with KRAS G12C-mutant advanced NSCLC. J Thorac Oncol 2026;21(4):103528. Abstract

Heist RS et al. Pan-tumor activity of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in patients with KRAS G12C-mutant advanced solid tumors. ASCO 2024;Abstract 3007.

Johnson ML et al. Efficacy and safety of 1L olomorasib plus pembrolizumab in KRAS G12C-mutant NSCLC: Results from LOXO-RAS-20001 and SUNRAY-01. WCLC 2025;Abstract MA02.06.

Nishio M et al. SUNRAY-01, a pivotal, global study of olomorasib (LY3537982) in combination with pembrolizumab with or without chemotherapy for 1L treatment in KRAS G12C-mutant advanced NSCLC. ASCO 2024;Abstract TPS218.

Skoulidis F et al. First-line (1L) divarasib plus pembrolizumab (pembro) in advanced or metastatic KRAS G12C+ non-small cell lung cancer (NSCLC): Results from the Krascendo-170 study. ASCO 2026;Abstract 8510.

Tan DSW et al. Safety and efficacy of elironrasib, a RAS(ON) G12C-selective inhibitor, in previously treated patients with KRAS G12C NSCLC. ESMO Asia Congress 2025;Abstract 977MO.

Faculty

Faculty

William K Oh

MD

Yale Cancer Center and Smilow Cancer Hospital, New Haven, Connecticut

Director of Precision Medicine

Yale School of Medicine, New Haven, Connecticut

Professor of Medicine, Section of Medical Oncology

Faculty

Mary-Ellen Taplin

MD

Harvard School of Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts

Professor of Medicine

TARGET AUDIENCE
This activity is intended for medical and radiation oncologists, urologists and other healthcare providers involved in the treatment of prostate cancer.

LEARNING OBJECTIVES

• Infer how various clinical and biological factors affect the risk of prostate cancer recurrence after local therapy, and design appropriate treatment plans for individual patients with consideration of the potential benefits and risks of new and established forms of hormonal therapy.
• Discuss the biological rationale for and available data with perioperative androgen deprivation therapy in combination with an androgen receptor pathway inhibitor for patients with high-risk localized or locally advanced prostate cancer, and review the potential clinical role of this novel strategy.
• Appraise published research findings on optimal management approaches for biochemical recurrence after local treatment for prostate cancer, and appropriately counsel patients regarding the potential benefits of FDA-approved systemic treatment options.
• Evaluate the published research database supporting the FDA approvals of secondary hormonal agents in the management of nonmetastatic prostate cancer, and apply this information in the discussion of nonresearch treatment options with patients.
• Explore available data with treatment intensification with cytotoxic therapy, secondary hormonal therapy or combinations of these approaches for metastatic hormone-sensitive prostate cancer, and effectively integrate these strategies into clinical management algorithms.
• Understand the potential side effects, including cardiovascular events, of hormonal agents commonly employed in the management of prostate cancer, and develop strategies to prevent, mitigate and manage these toxicities.
• Recall the design of ongoing clinical trials evaluating other novel hormonal agents and strategies for prostate cancer, and appropriately counsel patients about availability and participation.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 1.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

AMERICAN BOARD OF SURGERY (ABS) — CONTINUOUS CERTIFICATION (CC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
To receive credit for this activity, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Taplin — Advisory Committees: AstraZeneca Pharmaceuticals LP, BioNTech SE, Delphia Therapeutics, Flare Therapeutics, GSK, Johnson & Johnson, Novartis; Consulting Agreements: Johnson & Johnson; Data and Safety Monitoring Boards/Committees: Amgen Inc; Education: Curio Science, DAVA Oncology; Nonrelevant Financial Relationships: AXIS Medical Education Inc, MJH Life Sciences, Reach MD, UpToDate. Dr Oh — Advisory Committees: Analysis Group, AstraZeneca Pharmaceuticals LP, Biocartis, Novartis, Pfizer Inc; Stock Options/Stock — Public Companies: GeneDx.

MODERATOR — Dr Love  is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, and Verastem Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

This activity is supported by an educational grant from Johnson & Johnson.

Release date: September 2026
Expiration date: September 2027

Dr Taplin

Aggarwal R et al. PRESTO: A phase III, open-label study of intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer (AFT-19). J Clin Oncol 2024;42(10):1114-23. Abstract

Freedland SJ et al. Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med 2023;389(16):1453-65. Abstract

McKay RR et al. Recent advances in the management of high-risk localized prostate cancer: Local therapy, systemic therapy, and biomarkers to guide treatment decisions. Am Soc Clin Oncol Educ Book 2020;40:e241-52. Abstract

Pound CR et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281(17):1591-7. Abstract

Taplin ME et al. Perioperative (neoadjuvant and adjuvant) apalutamide (APA) + androgen deprivation therapy (ADT) vs placebo (PBO) + ADT with radical prostatectomy (RP) in high-risk localized or locally advanced prostate cancer (HR LPC/LAPC): Final analysis of the PROTEUS phase 3 study. ASCO 2026;Abstract LBA1.

Dr Oh

Agarwal N et al. PARP and androgen-signaling inhibition plus ADT in metastatic prostate cancer. N Engl J Med 2026;395(5):427-39. Abstract

Armstrong AJ et al. ARCHES 5-year survival with enzalutamide plus androgen-deprivation therapy in metastatic hormone-sensitive prostate cancer patients. Eur Urol 2026;89(5):396-403. Abstract

Armstrong AJ et al. Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol 2022;40(15):1616-22. Abstract

Attard G et al. Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: A randomized phase 3 trial. Nat Med 2025;31(12):4109-18. Abstract

Attard G et al. Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes. ASCO 2025;Abstract LBA5006.

Chi KN et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: Final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol 2021;39(20):2294-303. Abstract

Fizazi K et al. A phase III study of capivasertib (capi) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with PTEN deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC): CAPItello-281. ESMO 2025;Abstract 2383O.

Fizazi K et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): A multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet 2022;399(10336):1695-707. Abstract

Hussain M et al. Metastatic hormone-sensitive prostate cancer and combination treatment outcomes: A review. JAMA Oncol 2024;10(6):807-20. Abstract

Olmos D et al. BRCA1/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: Prevalence and impact on outcomes. Ann Oncol 2025;36(10):1190-202. Abstract

Saad F et al. Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial. J Clin Oncol 2024;42(36):4271-81. Abstract

Saad F et al. Efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase III ARANOTE trial. ESMO 2024;Abstract LBA68.

Smith MR et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med 2022;386(12):1132-42. Abstract

Tagawa ST et al. Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition). ESMO 2025;Abstract LBA6.

Faculty

Faculty

Karim Fizazi

MD, PhD

University of Paris Saclay, Centre Oscar Lambret, Lille, France

GETUG President

Faculty

Daniel George

MD

Duke University School of Medicine, Durham, North Carolina

Eleanor Easley Distinguished Chair, Professor of Medicine, Surgery and Urology

Duke Cancer Institute, Durham, North Carolina

ACS Research Professor, Co-Lead, DCI Center for Prostate and Urologic Cancers

Moderator

Elisabeth I Heath

MD, FACP

Mayo Clinic, Rochester, Minnesota

Chair, Department of Oncology, Professor of Oncology

TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of prostate cancer.

LEARNING OBJECTIVES

• Assess the clinical and biological factors in the selection of therapy for patients with metastatic hormone-sensitive prostate cancer (mHSPC) in order to optimally personalize treatment recommendations.
• Evaluate available Phase III data with novel AKT inhibitors in combination with hormonal therapy for patients with mHSPC and PTEN deficiency, and consider the potential role of this form of treatment.
• Implement a plan of care to recognize and manage side effects and toxicities associated with AKT inhibitors in preparation for their potential availability for patients with prostate cancer.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
To receive credit for this activity, the participant should review the CME information, watch the video and complete the evaluation.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Prof Fizazi — Honoraria, Former Institution: Advanced Accelerator Applications, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Janssen Biotech Inc, Merck, MSD, Novartis, Pfizer Inc. Dr George — Advisory Committees: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Candel Therapeutics, Convergent Therapeutics Inc, Dendreon Pharmaceuticals LLC, Johnson & Johnson, Merck, Novartis, Pfizer Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Eisai Inc, Johnson & Johnson, Novartis, Pfizer Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis Inc, Johnson & Johnson, Merck, Novartis, Pfizer Inc, pharmaand GmbH; Data and Safety Monitoring Boards/Committees: AstraZeneca Pharmaceuticals LP; Stock Options/Stock — Public Companies: Bristol Myers Squibb, Pfizer Inc; Nonrelevant Financial Relationships: IDEOlogy Health, MJH Life Sciences, Onclive, Targeted Oncology.

CONSULTING CLINICAL INVESTIGATORS — Neeraj Agarwal, MD, FASCO has no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Rana R McKay, MD, FASCO — Advisory Committees and Consulting Agreements: Ambrx, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Boundless Bio, Bristol Myers Squibb, Calithera Biosciences, Caris Life Sciences, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Janssen Biotech Inc, Lilly, Merck, Myovant Sciences, Neomorph, Nimbus Therapeutics, Novartis, Pfizer Inc, Sanofi, Seagen Inc, Sorrento Therapeutics, Telix Pharmaceuticals Limited, Tempus; Contracted Research: Artera, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis Inc, Incyte Corporation, Natera Inc, Oncternal Therapeutics.

MODERATOR
Dr Heath — Advisory Committees: (Personal Compensation): AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Caris Life Sciences, EMD Serono Inc, Gilead Sciences Inc, Novartis, Petauri Kinect, Pfizer Inc, Sanofi, Seagen Inc, Sumitomo Pharma America; Advisory Committees (to Institution): Janssen Biotech Inc; Consulting Agreements (Personal Compensation): Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Novartis, Sanofi; Consulting Agreements (to Institution): AstraZeneca UK, Novartis; Contracted Research (Grants): K36 Therapeutics, Novartis; Contracted Research (Research Support to Institution): Amgen Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BioXcel Therapeutics, Bristol Myers Squibb, Calithera Biosciences, Caris Life Sciences, Corcept Therapeutics Inc, Corvus Pharmaceuticals, Daiichi Sankyo Inc, Eisai Inc, Exelixis Inc, Fortis Therapeutics, Gilead Sciences Inc, GSK, Harpoon Therapeutics, Infinity Pharmaceuticals Inc, iTeos Therapeutics, Janssen Research and Development, K36 Therapeutics, Merck, MSD, Mirati Therapeutics Inc, Modra Pharmaceuticals, Novartis, Oncolys Biopharma, Peloton Therapeutics Inc, a wholly-owned subsidiary of Merck & Co Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, POINT Biopharma, Roche Laboratories Inc, Seagen Inc; Presenter/Co-Moderator: Curio Science; Speakers Bureaus: Sanofi; Steering Committees (Uncompensated): ORIC Pharmaceuticals; Travel Support: AstraZeneca UK; Nonrelevant Financial Relationships: Calibr-Skaggs Institute for Innovative Medicines.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, and Verastem Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.

Release date: September 2026
Expiration date: September 2027

de Bono J et al. Final overall survival and molecular data associated with clinical outcomes in patients receiving ipatasertib and abiraterone in the phase 3 IPATential150 trial. Eur Urol 2025;87(6):672-82. Abstract

Fizazi K et al. A phase III study of capivasertib (capi) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with PTEN deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC): CAPItello-281. ESMO 2025;Abstract 2383O.

George DJ et al. Patient reported outcomes (PRO) and tolerability of capivasertib (capi) plus abiraterone (abi) versus placebo (pbo) plus abi in patients (pts) with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC): CAPItello-281. Genitourinary Cancers Symposium 2026;Abstract 14.

Iyengar NM et al. Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: Expert opinion. NPJ Breast Cancer 2025;12(1):16. Abstract

Kisiel F et al. Prognostic significance of PTEN loss in prostate cancer: A meta-analysis of Gleason grade and clinical outcomes. Cancers (Basel) 2025;17(17):2862. Abstract

Lotan T et al. Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH. Mod Pathol 2016;29(8):904-14. Abstract

Maylin ZR et al. Therapeutic exploitation of neuroendocrine transdifferentiation drivers in prostate cancer. Cells 2024;13(23):1999. Abstract

Sweeney C et al. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): A multicentre, randomised, double-blind, phase 3 trial. Lancet 2021;398(10295):131-42. Abstract

Tortorella E et al. AR and PI3K/AKT in prostate cancer: A tale of two interconnected pathways. Int J Mol Sci 2023;24(3):2046. Abstract